A novel genome engineering method, known as prime assembly, is set to revolutionize genome editing by enabling the precise integration of long DNA fragments at targeted locations within living cells. This advancement addresses the limitations of current genome editing techniques, which often rely on untargeted gene delivery and short DNA edits tailored to individual patients.
Published in Nature, the study highlights how prime assembly utilizes CRISPR-targeted dual flap synthesis, facilitating the development of universal gene therapies. Unlike traditional methods that depend on homology-directed repair, prime assembly shows efficacy in both dividing and non-dividing cells, significantly broadening its therapeutic applications.
The method’s ability to perform targeted exon recoding and megabase-scale rearrangements in primary human cells positions it as a promising tool for correcting multiple mutations simultaneously. As researchers refine this approach, they aim to enhance the delivery of prime assembly components to disease-relevant cells, potentially transforming treatment strategies for genetic disorders with unmet clinical needs.
Get started today with Solo access →
